Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 11/20 | 0.59 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9603360 | 1.00 | AGTR2 (0.59) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL9033443 | 1.00 | AGTR2 (0.59) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL3784713 | 1.00 | AGTR2 (0.59) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL9033440 | 1.00 | AGTR2 (0.59) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL5635251 | 0.89 | AGTR2 (0.57) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL5635255 | 0.89 | AGTR2 (0.57) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL5754489 | 0.89 | AGTR2 (0.57) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL18154378 | 0.89 | BDKRB2 (0.50) | AGTR2BDKRB2CTSLCTSBCTSK | |
| SCHEMBL23461721 | 0.88 | AGTR2 (0.52) | AGTR2BDKRB2S1PR5 | |
| SCHEMBL6515997 | 0.88 | AGTR2 (0.56) | AGTR2BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | AGTR2 3045/4885BDKRB2 111/4885CTSL 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.